EGFR and neoplasm: In conclusion, the understating of the molecular basis of tumor heterogeneity in EGFR mutated NSCLC patients is crucial for designing combinatorial approaches targeting the bypass signaling pathways, preventing the onset of resistance mechanisms, and prolonging patient survival.